Cooper Companies Inc

Cooper Companies Inc(COO)股票分析

$71.170

+0.214 (+0.30%)收盤時

Loading chart…
High
71.500
Open
71.180
VWAP
71.11
Vol
1.01M
Mkt Cap
17.45B
Low
70.664
Amount
71.91M
EV/EBITDA, TTM
64.67

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee.

AI analysis of Cooper Companies Inc (COO)

hold

Currently, Cooper Companies Inc (COO) is not a strong buy. The stock is priced at $71.17, which is below the average analyst price target of $76. This indicates potential upside, but the stock has a low RSI of 20.795, suggesting it is oversold. However, the company has recently reported a significant decline in net income, with a net loss of $77.9 million in Q2 2026, which raises concerns about its financial health. The main risk is the projected sales growth slowing to 4.2% over the next 12 months, which is below the healthcare sector average.

Analyst Ratings (15)

+26.92% upside
Buy
10 Buy
5 Hold
0 Sell
Current: 71.17
最低
73.00
平均
90.33
最高
100.00

Citi

2026-08-13

目標價

$80

Neutral

UBS

2026-07-28

目標價

$75

Neutral

Citi

2026-07-08

目標價

$76

Neutral

Needham

2026-06-05

目標價

$86

Buy

JPMorgan

2026-06-05

目標價

$71

Neutral

估值指標

The current forward P/E ratio for Cooper Companies Inc (COO) is 14.79, compared to its 5-year average forward P/E of 23.35.

Forward P/E

Undervalued
5Y Average P/E
23.35
Current P/E
14.79
高估
28.34
低估
18.36

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
20.34
Current EV/EBITDA
64.67
高估
35.45
低估
5.24

Forward P/S

Undervalued
5Y Average P/S
4.49
Current P/S
3.14
高估
5.47
低估
3.51

Alphio AI Price Scenarios for COO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%COO

$100.88

情境價格

B

Base

Base · 50%COO

$92.29

情境價格

B

Bear

Bear · 25%COO

$83.71

情境價格

Whales holding COO

L

Longview Partners (Guernsey) Limited

+ HoldingCOO

+5.80%

3M Return

H

Heartland Advisors, Inc.

+ HoldingCOO

+5.63%

3M Return

D

Diamond Hill Capital Management, Inc.

+ HoldingCOO

+5.48%

3M Return

T

The London Company of Virginia, LLC

+ HoldingCOO

+3.03%

3M Return

S

Staley Capital Advisers, Inc.

+ HoldingCOO

+1.21%

3M Return

F

Findlay Park Partners LLP

+ HoldingCOO

+0.39%

3M Return

事件時間軸

2026-06-05 (ET)

16:30:00

Nasdaq Plummets Nearly 4% as Semiconductor Stocks Weaken

12:10:00

Cooper Companies Stock Rises 7.5% to $66.70

12:10:00

Major U.S. Stocks Broadly Lower at Noon, Semiconductor and AI Stocks Under Pressure

10:10:00

Cooper Companies Stock Rises 6.9% to $66.27

10:00:00

Cooper Companies Stock Rises $4.01 to $66.03

資訊

COO FAQ — answered by Alphio AI

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

Currently, Cooper Companies Inc (COO) is not a strong buy. The stock is priced at $71.17, which is below the average analyst price target of $76. This indicates potential upside, but the stock has a low RSI of 20.795, suggesting it is oversold. However, the company has recently reported a significant decline in net income, with a net loss of $77.9 million in Q2 2026, which raises concerns about its financial health. The main risk is the projected sales growth slowing to 4.2% over the next 12 months, which is below the healthcare sector average.

15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始